HK1064096A1 - Purine derivatives as a2b adenosine receptor antagonists. - Google Patents

Purine derivatives as a2b adenosine receptor antagonists.

Info

Publication number
HK1064096A1
HK1064096A1 HK04106852A HK04106852A HK1064096A1 HK 1064096 A1 HK1064096 A1 HK 1064096A1 HK 04106852 A HK04106852 A HK 04106852A HK 04106852 A HK04106852 A HK 04106852A HK 1064096 A1 HK1064096 A1 HK 1064096A1
Authority
HK
Hong Kong
Prior art keywords
optionally substituted
receptor antagonists
adenosine receptor
purine derivatives
sup
Prior art date
Application number
HK04106852A
Other languages
English (en)
Inventor
Jeff A Zablocki
Vaibhav Varkhedkar
Venkata Palle
Dengming Xiao
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of HK1064096A1 publication Critical patent/HK1064096A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HK04106852A 2001-06-29 2004-09-09 Purine derivatives as a2b adenosine receptor antagonists. HK1064096A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30220801P 2001-06-29 2001-06-29
PCT/US2002/020631 WO2003002566A1 (en) 2001-06-29 2002-06-27 Purine derivatives as a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
HK1064096A1 true HK1064096A1 (en) 2005-01-21

Family

ID=23166757

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04106852A HK1064096A1 (en) 2001-06-29 2004-09-09 Purine derivatives as a2b adenosine receptor antagonists.

Country Status (11)

Country Link
US (2) US6770651B2 (xx)
EP (1) EP1401837B1 (xx)
JP (1) JP4335000B2 (xx)
KR (2) KR100883292B1 (xx)
AT (1) ATE307132T1 (xx)
CA (1) CA2451244C (xx)
DE (1) DE60206756T2 (xx)
DK (1) DK1401837T3 (xx)
ES (1) ES2247356T3 (xx)
HK (1) HK1064096A1 (xx)
WO (1) WO2003002566A1 (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
ATE355291T1 (de) * 2001-12-18 2006-03-15 Cv Therapeutics Inc A2a adenosinrezeptorantagonisten
DK1622908T3 (da) * 2003-05-06 2008-11-17 Cv Therapeutics Inc Xanthin-derivater som A2B adenosin-receptor-antagonister
NL1023355C2 (nl) * 2003-05-07 2004-11-09 Oce Tech Bv Hot melt inkt omvattend een mengsel van kleurstoffen.
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
JP2006528199A (ja) * 2003-07-22 2006-12-14 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシン受容体拮抗薬
WO2005047268A2 (en) * 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
US20080280926A1 (en) * 2003-12-16 2008-11-13 Palle Venkata P Phosphodiesterase Inhibitors
TWI427077B (zh) 2004-12-30 2014-02-21 Astex Therapeutics Ltd 吡唑化合物及其用途和含有彼之藥學組成物
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
US20070225304A1 (en) * 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
JP5474354B2 (ja) 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド 医薬化合物
US8846697B2 (en) * 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
US7470697B2 (en) * 2006-09-01 2008-12-30 Adenosine Therapeutics, Llc Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
US20090099212A1 (en) * 2007-10-16 2009-04-16 Jeff Zablocki A3 adenosine receptor antagonists
JP2011511073A (ja) * 2008-02-07 2011-04-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒ７活性化物質による膀胱の疾患の治療
CN102015712A (zh) 2008-03-26 2011-04-13 阿德维纳斯治疗私人有限公司 作为腺苷受体拮抗剂的杂环化合物
US20110118276A1 (en) * 2008-07-16 2011-05-19 Edward Leung Methods of treating atherosclerosis
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
US8859566B2 (en) 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
PL2408775T3 (pl) * 2009-03-20 2015-10-30 Alfasigma Spa Utlenione pochodne triazolilopurynowe użyteczne jako ligandy receptora adenozynowego a2a i ich zastosowanie jako leków
JP5843778B2 (ja) * 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
CN103237548A (zh) 2010-06-30 2013-08-07 吉利德科学股份有限公司 A2b腺苷受体拮抗剂用于治疗肺高血压的应用
EP2616470B1 (en) 2010-09-13 2016-10-12 Advinus Therapeutics Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
WO2016087665A2 (en) * 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
EP3450433B1 (en) * 2016-04-26 2021-08-18 Sumitomo Dainippon Pharma Co., Ltd. Purine derivatives as tlr7 inhibitors for treating e.g. systemic lupus erythematosus
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
PE20220166A1 (es) * 2019-03-05 2022-01-28 F Star Therapeutics Inc Compuestos, composiciones y metodos para el tratamiento de enfermedad
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
MXPA02002262A (es) 1999-08-31 2002-09-30 Univ Vanderbilt Antagonistas selectivos de los receptores adenosina a2b.
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
ATE355291T1 (de) * 2001-12-18 2006-03-15 Cv Therapeutics Inc A2a adenosinrezeptorantagonisten

Also Published As

Publication number Publication date
JP4335000B2 (ja) 2009-09-30
DK1401837T3 (da) 2005-11-07
US20040209899A1 (en) 2004-10-21
DE60206756D1 (de) 2006-03-02
CA2451244C (en) 2012-01-17
KR100883292B1 (ko) 2009-02-11
US7238700B2 (en) 2007-07-03
EP1401837A1 (en) 2004-03-31
CA2451244A1 (en) 2003-01-09
KR100897219B1 (ko) 2009-05-14
US6770651B2 (en) 2004-08-03
US20030064999A1 (en) 2003-04-03
WO2003002566A1 (en) 2003-01-09
ES2247356T3 (es) 2006-03-01
EP1401837B1 (en) 2005-10-19
KR20080081208A (ko) 2008-09-08
KR20040023634A (ko) 2004-03-18
ATE307132T1 (de) 2005-11-15
JP2004536102A (ja) 2004-12-02
DE60206756T2 (de) 2006-07-13

Similar Documents

Publication Publication Date Title
HK1064096A1 (en) Purine derivatives as a2b adenosine receptor antagonists.
LUC00155I2 (xx)
NL300927I1 (nl) tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
MXPA04003795A (es) Compuestos de pirimidina y composiciones farmaceuticas que contienen los compuestos.
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
WO2003022216A3 (en) Biaryl substituted purine derivatives as potent antiproliferative agents
TW200615265A (en) Organic compounds
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
BR0008770A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica
BG106289A (en) Purine derivatives
RS20050311A (xx) Odabrani cgrp antagonisti, postupci za njihovo dobijanje i njihovo korišćenje u vidu farmaceutskih kompozicija
ZA200201831B (en) Quinazoline derivatives.
TW200626145A (en) Heterocyclic compounds and thrombopoietin receptor activators
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
ZA200305116B (en) Purine derivatives as purinergic receptor antagonists.
CA2359646A1 (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-.beta.-cyclodextrin or 2-hydroxypropyl-.beta.-cyclodextrin and method
WO2003022219A3 (en) Biarylamino purine antiproliferative agents
WO2006110884A8 (en) 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists
WO2003022805A3 (en) Heterocycle substituted purines as antiproliferative agents
GB9908410D0 (en) Pyridines
NZ233015A (en) Acryloyl-substituted pyrrole derivatives (distamycin a analogues) and pharmaceutical compositions
TW333527B (en) Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
DE60228817D1 (de) THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN
WO2003068776A1 (fr) Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine
MXPA04003479A (es) Novedosos derivados de 4-fenil-4[1h-imidazol-2-il]piperidina sustituida y su uso como agonistas selectivos no peptidicos de opiodes delta.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220626